Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics.

Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics. Abstract Text:

David S Hong,Laura S Angelo,Razelle Kurzrock,David S Hong,Laura S Angelo,Razelle Kurzrock,

Interleukin-6 (IL-6) plays a major role in the response to injury or infection and is involved in the immune response, inflammation, and hematopoiesis. Its deregulation impacts numerous disease states, including many types of cancer. Consequently, modulating IL-6 may be an innovative therapeutic strategy in several diseases. A review of relevant published literature regarding IL-6 and its receptor was performed. In addition, a review of the relevance of this cytokine system to human illness, particularly in cancer, was undertaken. IL-6 is a pleiotropic cytokine that is involved in the physiology of virtually every organ system. Aberrant expression of this cytokine has been implicated in diverse human illnesses, most notably inflammatory and autoimmune disorders, coronary artery and neurologic disease, gestational problems, and neoplasms. In cancer, high levels of circulating IL-6 are observed in almost every type of tumor studied and predict a poor outcome. Furthermore, elevated IL-6 levels are associated strongly with several of the striking phenotypic features of cancer. Several molecules have been developed recently that target the biologic function of IL-6. Early results in the clinic suggest that this strategy may have a significant salutary impact on diverse tumors. The field of cytokine research has yielded a deep understanding of the fundamental role of IL-6 and its receptor in health and disease. Therapeutic targeting of IL-6 and its receptor in cancer has strong biologic rationale, and there is preliminary evidence suggesting that targeting of the IL-6 system may be beneficial in the treatment of cancer.

Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics. Publishing Authors By Initials

DS Hong,LS Angelo,R Kurzrock,DS Hong,LS Angelo,R Kurzrock,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics. Journal Published:

PUBLICATION TYPE: Review

Journal: Cancer

VOLUME: 110

Page Numbers: 1911-28

Journal Abbreviation: Cancer

ISSN: 0008-543X

DAY: 1

MONTH: Nov

YEAR: 2007

Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics. Information

Number of References: 168

LANGUAGE: eng

NlmUniqueID: 374236

Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics.

AFFILIATION: Phase I Program, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics Related Publications

• Beta1 integrin expression pattern in transitional urothelium does not allow for efficient stem cell enrichment as in other epithelia.
• Complete bladder duplication presenting as incontinence in an 11-year-old girl.
• Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells.
• Cutaneous castleman's disease responds to anti interleukin-6 treatment.
• Development and validation of the fecal incontinence and constipation quality of life measure in children with spina bifida.
• Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials.
• How do we measure hypospadias outcomes?
• Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides.
• Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics.
• Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
• Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
• Non-surgical management of multicystic dysplastic kidney.
• Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies.
• Short stay pyeloplasty: variables affecting pain and length of stay.
• Studies in target-based treatment.
• The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes.
• [Vinca rosea in the treatment of hemoblastoses and similar clinical pictures.]